Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 701 - 750 out of 46,052

Document Document Title
WO/2013/181472
Provided herein are methods and compositions for the treatment of stress related, particularly post-traumatic stress disorder (PTSD) and co-morbid disorders using neuropeptide.  
WO/2013/181454
The current invention involves the use of protein lectins produced by plants including the non-toxic carbohydrate binding subunits (B subunits) of plant "AB toxins" (PTB lectins) as delivery vehicles for mobilizing associated drug substa...  
WO/2013/181618
Non-familial late-onset Alzheimer's disease (LOAD), a condition associated with the accumulation of the amyloid precursor protein- derived (APP) Abeta fragment in the brain, can be the consequence of combined genetic and environmental ri...  
WO/2013/179144
The current application relates to the use of a compound selected from the group consisting of camptothecin and its analog, 10-hydroxy camptothecin, topotecan, irinotecan, 18-beta-glycyrrhetinic acid and its analog, carbinoxolone, etopos...  
WO/2013/179910
A medicine effective in preventing and/or treating peripheral neuropathic pain, such as allodynia, caused by an anti-cancer drug treatment; wherein the medicine contains thrombomodulin as an active ingredient.  
WO/2013/181296
The present disclosure provides Diels-Alder adducts of chalcone and prenylphenyl moieties capable of modulating the activity of cannabinoid receptors, and to oligomers of flavan-3-ol capable of modulating fat absorption and storage. Such...  
WO/2013/181451
Improved methods of treating multiple sclerosis and/or psoriasis using prodrugs of methyl hydrogen fumarate are disclosed. The methods comprise administering certain prodrugs of methyl hydrogen fumarate. The methods are able to achieve h...  
WO/2013/181296
The present disclosure provides Diels-Alder adducts of chalcone and prenylphenyl moieties capable of modulating the activity of cannabinoid receptors, and to oligomers of flavan-3-ol capable of modulating fat absorption and storage. Such...  
WO/2013/179049
The invention relates to spiro derivatives, to the use of said derivatives in treating diseases and conditions mediated by modulation of voltage-gated sodium channels, to compositions containing said derivatives and processes for their p...  
WO/2013/180271
Provided are a fluorine-containing amino acid prodrug represented by general formula (I) that makes a fluorine-containing amino acid which is a group 2 metabotropic glutamate receptor agonist into a prodrug, or a pharmacologically accept...  
WO/2013/180265
Provided is a compound having an excellent JAK inhibitory activity and therefore useful as a prophylactic or therapeutic agent for autoimmune diseases (e.g., rheumatoid arthritis, psoriasis, inflammatory bowel disease, Sjogren's syndrome...  
WO/2013/180240
The purpose of the present invention is to provide a general anesthetic medicine which can prevent and/or alleviate an anesthetic-induced neuropathy in the brain (preferably the developing brain). The present invention relates to a medic...  
WO/2013/179024
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof : (I) in which m, n, W, X, Y, Z, R1, R2, R3 and R4 are as defined in the specification, for use in the treatment or prevention of a dis...  
WO/2013/180066
The purpose of the invention is to provide a compound represented by general formula (1) having an excellent prophylactic and therapeutic effect on autoimmune disease, inflammation, allergies, and the like; the compound inhibiting at lea...  
WO/2013/178322
The present invention provide compounds of Formula (I) used as BACE inhibitors for the treatment of neurodegenerative diseases  
WO/2013/179309
The present invention relates to a new series of chemical compounds with a novel norneolignan skeleton (chemical formula I) possessing a biological activity on the central nervous system (CNS), especially memory-enhancing and acetylcholi...  
WO/2013/179153
Disclosed are compounds of formula (I) or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. Provided are also pharmaceutical compositions comprising an effective amount...  
WO/2013/181228
Fusion proteins comprising a DNA binding domain, e.g., a TAL effector repeat array or zinc finger array, and a catalytic domain comprising a sequence that catalyzes hydroxylation of methylated cytosines in DNA, and methods of use thereof.  
WO/2013/181135
The disclosure relates to quinazoline derivatives, compositions, and methods related thereto. In certain embodiments, the disclosure relates to inhibitors of NADPH-oxidases (Nox enzymes) and/or myeloperoxidase.  
WO/2013/174245
Disclosed in the present invention are a hederagenin derivative and the preparation method and uses thereof, and the general formula of the derivative is (I). The preparation method is as follows: the derivative can be obtained via acyla...  
WO/2013/177062
The present invention relates to compositions and methods for improving the safety of blood-brain barrier receptor-mediated blood-brain barrier transport.  
WO/2013/176885
The disclosure is directed to the detection, early diagnosis, determination of the severity, and treatment of Alzheimer's disease (AD). A number of biomarkers and combination of biomarkers are disclosed for the determination of AD, inclu...  
WO/2013/175053
Compounds of formula (I), wherein R1 is as defined in the claims, exhibit COMT enzyme inhibiting activity and are thus useful as COMT inhibitors.  
WO/2013/176567
The invention relates to the field of medicine and the pharmaceutical-chemical industry, and specifically to the field of neurology, and concerns new compositions containing memantine and melatonin. It has been established that a strengt...  
WO/2013/174133
Disclosed is an application of SBT in preventing and treating diabetes mellitus vasculopathy and neuropathy. The SBT can significantly increase the expression of p-insulin receptor β and the ratio of p-insulin receptor β to total insul...  
WO/2013/176503
The present invention relates to a neurodegenerative disease therapeutic agent, and, more specifically, provides a composition containing, as an active ingredient, an ALK (anaplastic lymphoma kinase) activity or expression inhibiting sub...  
WO/2013/177116
Provided herein is a method of treating neuromyelitis optica (NMO) in an animal or human subject comprising administering to the subject a composition comprising a therapeutically effective amount of an Fc region modified anli-AQP4 antib...  
WO/2013/175359
The invention relates to the compounds of formula I and formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an ef...  
WO/2013/177224
The invention provides novel compounds having the general formula (I) and pharmaceutically acceptable salts thereof, wherein the variables RA, subscript n, ring A, X2, L, subscript m, X1, B, R1, R2, R3, R4, R5 and RN have the meaning as ...  
WO/2013/173941
Provided are a peptide comprising the amino acid sequence of DEAQETAVSSHEQD, the polynucleotide encoding it, the uses of said peptide for the treatment of the symptoms associated with pain and for the inhibition of the activity of influe...  
WO/2013/175215
Compounds of formula (I) are of use in the modulation of Kv3.1, Kv.3.2 and Kv3.3 channels and have utility in the treatment or prevention of related disorders.  
WO/2013/175508
The present invention provides stable pharmaceutical composition of Aripiprazole. In one embodiment, the present invention encompasses the use of crospovidone having peroxide content of less than 80 ppm, advantageously less than 50 ppm, ...  
WO/2013/177494
The present invention relates to a pharmaceutical composition for use in the treatment of cognitive symptoms of schizophrenia comprising administering a therapeutically effective amount of a selective agonist of neuronal nicotinic acetyl...  
WO/2013/176624
The present invention pertains to methods of treating stroke by administering anti-microRNA-320, optionally in conjunction with tissue plasminogen activator (tPA), as well as methods of reducing blood-brain barrier permeability by admini...  
WO/2013/177510
This application is directed to α-neuronal nicotinic receptor agonists selective for α7-subtype that are useful for improving cognition impairment in patients having schizophrenia, a schizophreniform disorder or a related schizophrenia...  
WO/2013/175376
The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount ...  
WO/2013/174882
The invention relates to a composition comprising NADH and D-galactose for treating a circadian rhythm disorder, in particular further comprising vitamins and/or coenzymes and/or minerals.  
WO/2013/177498
The present invention relates to pharmaceutical compositions for use in the treatment of cognitive symptoms of schizophrenia or a related schizophrenia spectrum psychotic disorder, comprising administering a therapeutically effective amo...  
WO/2013/177367  
WO/2013/175047
Use of a compound of formula (I) to manufacture a medicament for treating Gaucher's disease in a human subject, a pharmaceutical composition comprising a compound of formula (I), compounds of formula (Ib) and method for obtaining said co...  
WO/2013/177024
The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic α7 receptor and may be useful for the treatment of various di...  
WO/2013/177570
Provided herein are methods for treating a disease or condition of the central nervous system. The methods include administering to the subject having or at risk of having the disease or condition a composition comprising RLIP76. Also pr...  
WO/2013/175316
A method for treating Huntington's disease in a mammal in need thereof is disclosed. The method comprises administering to the mammal an effective amount of a compound of Structural Formula I, or a pharmaceutically acceptable salt thereo...  
WO/2013/177104  
WO/2013/174780
The present invention provides for compounds of Formula I and various embodiments thereof, and compositions comprising compounds of Formula I and various embodiments thereof. In compounds of Formula I, the groups R1, R2, R3, R4, R5, R6, ...  
WO/2013/175315
The present invention generally concerns particular methods and compositions for treatment of a neurodegenerative disease, such as Alzheimer's Disease. In particular embodiments, there is a composition comprising Parthenolide and a secon...  
WO/2013/175205
NOVEL COMPOUNDS The invention relates to spiro derivatives, to the use of said derivatives intreating diseases and conditions mediated by modulation of voltage-gated sodium channels, to compositions containing said derivatives and proces...  
WO/2013/175211
The present invention relates to the prophylaxis of acute noise- induced hearing loss by administering a compound of formula (I): wherein: W is group (Wa), group (Wb) or group (Wc):  
WO/2013/175206
The invention relates to spiro derivatives, to the use of said derivatives in treating diseases and conditions mediated by modulation of voltage-gated sodium channels, to compositions containing said derivatives and processes for their p...  
WO/2013/176220
The present invention provides a circadian rhythm-regulating agent which comprises an inhibitor capable of inhibiting vasopressin receptors V1a and V1b as an active ingredient.  

Matches 701 - 750 out of 46,052